Industry's PMS activities branded "unsatisfactory"
This article was originally published in RAJ Devices
Executive Summary
Postmarket surveillance activities by medical device manufacturers in the UK remain unsatisfactory and some companies still view their clinical trial data as private property, despite this being unethical and against trade association guidance. These were some of the key points to emerge from a meeting of medtech experts hosted by the UK Medicines and Healthcare products Regulatory Agency.